Study of Tirabrutinib (ONO-4059) in Patients With Primary Central Nervous System Lymphoma (PROSPECT Study)

Trial ID or NCT#

NCT04947319

Status

recruiting iconRECRUITING

Purpose

This study will evaluate the efficacy, safety, and pharmacokinetics of tirabrutinib monotherapy in patients with relapsed or refractory PCNSL (Part A), and tirabrutinib in combination with one of two different high dose methotrexate based regimens (methotrexate/ temozolomide/rituximab or rituximab/methotrexate/procarbazine/ vincristine) as first line therapy in patients with newly diagnosed, treatment naïve PCNSL (Part B)

Official Title

An Open-label Phase II Study to Investigate the Efficacy, Safety, and Pharmacokinetics of Tirabrutinib in Patients With Primary Central Nervous System Lymphoma (PCNSL)

Eligibility Criteria

Ages Eligible for Study: Older than 18 Years
Sexes Eligible for Study: All
Accepts Healthy Volunteers: No
Show Less

Investigator(s)

Neel K. Gupta
Neel K. Gupta
Hematologist-Oncologist
Clinical Associate Professor, Medicine - Oncology Clinical Assistant Professor, Medicine - Hematology

Contact us to find out if this trial is right for you.

Contact

Hari Priya Yerraballa
+1 650-724-9363

SEND MESSAGE

View on ClinicalTrials.gov